Search
Propranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigational[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904] … Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.
Categories: Antihypertensive Agents Indicated for Hypertension, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesIsosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalRefer to these drug entries for more information. … Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued.
Gefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Eluxadoline
go.drugbank.com/drugs/DB09272ApprovedInvestigationalEluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). … Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAtorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigationalPrescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. … [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaEszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigational[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity[A179827], offering a safer alternative to other drugs used for insomnia. … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar works to block bile acid synthesis.[A264234] … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Omidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigational[A258938,A258943,L46048] This type of cell therapy benefits patients that require stem cell transplantation as a treatment for blood cancers for whom a related or unrelated donor cannot be found due to … Umbilical blood cord cells are expanded _ex-vivo_ and [nicotinamide] (a form of vitamin B3) is used as an active agent in the culture system to inhibit the differentiation and increase the functionality
Ropinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Cinoxacin
go.drugbank.com/drugs/DB00827ApprovedWithdrawnSynthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use